白蛋白治疗对失代偿期肝硬化患者全身与门静脉血流动力学及全身炎症的影响
本研究基于Pilot-PRECIOSA与INFECIR-2两项试验数据,探讨20%白蛋白对失代偿期肝硬化伴或不伴细菌感染患者低白蛋白血症、循环功能障碍、门脉高压及全身炎症的影响。长期高剂量白蛋白可使血清白蛋白正常化、改善循环稳定性与左心室功能并降低细胞因子水平,且不显著改变门静脉压力;短期白蛋白联合抗生素亦降低细胞因子水平。
要点
- 长期高剂量白蛋白(1.5 g/kg每周)可正常化血清白蛋白并改善循环稳定性与左心室功能。
- 长期高剂量白蛋白降低白细胞介素6等细胞因子水平,但门静脉压力无显著变化。
- 伴细菌感染患者中,白蛋白联合抗生素较单用抗生素显著降低血浆细胞因子水平。
核心结论
- 基于Pilot-PRECIOSA与INFECIR-2两项试验数据分析,白蛋白治疗降低失代偿期肝硬化患者的全身炎症与循环功能障碍,这些效应可能解释白蛋白治疗对患者结局的益处。
研究设计与样本
- 前瞻性研究Pilot-PRECIOSA纳入18例无细菌感染的失代偿期肝硬化患者,评估长期(12周)低剂量(1 g/kg体重每2周)与高剂量(1.5 g/kg每周)白蛋白治疗的效果。
- INFECIR-2为随机对照试验,利用其78例细菌感染患者的生物样本库样本,评估短期(1周)单用抗生素与白蛋白联合抗生素(第1天1.5 g/kg、第3天1 g/kg)对血浆细胞因子的影响。
主要发现
- Pilot-PRECIOSA研究中许多患者循环功能障碍与全身炎症极不稳定,血浆肾素与白细胞介素6水平出现剧烈且可逆的峰值。
- 长期高剂量白蛋白(而非低剂量)与血清白蛋白水平正常化、循环与左心室功能稳定性改善及血浆细胞因子(白细胞介素6、粒细胞集落刺激因子、白细胞介素1受体拮抗剂、血管内皮生长因子)水平降低相关,门静脉压力无显著变化。
- INFECIR-2研究中,接受白蛋白的患者血浆细胞因子水平显著降低,证实了Pilot-PRECIOSA观察到的白蛋白免疫调节效应。
关键数值与推荐
- Pilot-PRECIOSA长期低剂量方案为1 g/kg体重每2周,高剂量方案为1.5 g/kg每周,疗程12周。
- INFECIR-2短期白蛋白方案为第1天1.5 g/kg、第3天1 g/kg,联合抗生素使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated the effect of albumin treatment (20% solution) on hypoalbuminemia, cardiocirculatory dysfunction, portal hypertension, and systemic inflammation in patients with decompensated cirrhosis with and without bacterial infections. METHODS: We performed a prospective study to assess the effects of long-term (12 weeks) treatment with low doses (1 g/kg body weight every 2 weeks) and high doses (1.5 g/kg every week) of albumin on serum albumin, plasma renin, cardiocirculatory function, portal pressure, and plasma levels of cytokines, collecting data from 18 patients without bacterial infections (the Pilot-PRECIOSA study). We also assessed the effect of short-term (1 week) treatment with antibiotics alone vs the combination of albumin plus antibiotics (1.5 g/kg on day 1 and 1 g/kg on day 3) on plasma levels of cytokines in biobanked samples from 78 patients with bacterial infections included in a randomized controlled trial (INFECIR-2 study). RESULTS: Circulatory dysfunction and systemic inflammation were extremely unstable in many patients included in the Pilot-PRECIOSA study; these patients had intense and reversible peaks in plasma levels of renin and interleukin 6. Long-term high-dose albumin, but not low-dose albumin, was associated with normalization of serum level of albumin, improved stability of the circulation and left ventricular function, and reduced plasma levels of cytokines (interleukin 6, granulocyte colony-stimulating factor, interleukin 1 receptor antagonist, and vascular endothelial growth factor) without significant changes in portal pressure. The immune-modulatory effects of albumin observed in the Pilot-PRECIOSA study were confirmed in the INFECIR-2 study. In this study, patients given albumin had significant reductions in plasma levels of cytokines. CONCLUSIONS: In an analysis of data from 2 trials (Pilot-PRECIOSA study and INFECIR-2 study), we found that albumin treatment reduced systemic inflammation and cardiocirculatory dysfunction in patients with decompensated cirrhosis. These effects might be responsible for the beneficial effects of albumin therapy on outcomes of patients with decompensated cirrhosis. ClinicalTrials.gov, Numbers: NCT00968695 and NCT03451292.
引用
- Fernández J, Clària J, Amorós A, et al. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology. 2019. PMID: 30905652. doi:10.1053/j.gastro.2019.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。